PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pre-index antibiotic and organ-support burden flag ICU MDRO risk

multidrug-resistant organismsantimicrobial stewardshipcarbapenem resistanceCRABCRECRPAintensive care unitventilator-associated pneumoniabloodstream infectionprocalcitoninpropensity score matchingrisk stratificationobservational cohort Infectious Disease / Antimicrobials

Background Information

MDRO risk factors in ICUs spotlight antimicrobial stewardship needs.

Multidrug-resistant organism (MDRO) infections significantly impact patient outcomes in intensive care units (ICUs), necessitating targeted prevention and stewardship efforts. MDRO infections were seen in 10.4% of ICU admissions. Factors such as severity of illness, prior antibiotic exposure, mechanical ventilation, and inflammatory markers were associated with MDRO risk. These findings can guide ICU risk stratification efforts, but further validation and evaluation of time-dependent exposures are necessary. Identifying MDRO risk factors in ICUs supports improved antimicrobial stewardship.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Ma XJ, Chen MN

Citation: Ma XJ, Chen MN Pathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patients. Frontiers in public health. 2026;14:1821168. doi:10.3389/fpubh.2026.1821168

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.